Investors bet on 'post-Ozempic economy' foodtech

GLP-1 drugs are rewriting consumer behavior, and investors are pouring money into food brands and tech designed for the 'post-Ozempic' reality. This signals a future where gut health and mindful eating are increasingly central, whether or not you're on a weight-loss drug.